title: Treatment and vaccines for severe acute respiratory syndrome.
abstract: The causative agent of severe acute respiratory syndrome (SARS), which affected over 8000 individuals worldwide and was responsible for over 700 deaths in the 2002-2003 outbreak, is a coronavirus that was unknown before the outbreak. Although many different treatments were used during the outbreak, none were implemented in a controlled fashion. Thus, the optimal treatment for SARS is unknown. Since the outbreak, much work has been done testing new agents against SARS using in-vitro methods and animal models. In addition, global research efforts have focused on the development of vaccines against SARS. Efforts should be made to evaluate the most promising treatments and vaccines in controlled clinical trials, should another SARS outbreak occur.
authors.affiliation: Department of Pneumology, Hannover Medical School, Hannover, Germany. david.groneberg@charite.de
authors.forename: David A
authors.initials: DA
authors.lastname: Groneberg
authors.forename: Susan M
authors.initials: SM
authors.lastname: Poutanen
authors.forename: Donald E
authors.initials: DE
authors.lastname: Low
authors.forename: Hartmut
authors.initials: H
authors.lastname: Lode
authors.forename: Tobias
authors.initials: T
authors.lastname: Welte
authors.forename: Peter
authors.initials: P
authors.lastname: Zabel
mesh_terms: D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use*; D004196:Disease Outbreaks / Q000517:prevention & control*; D006801:Humans; D045473:Severe acute respiratory syndrome-related coronavirus / Q000187:drug effects / Q000276:immunology / Q000472:pathogenicity; D045169:Severe Acute Respiratory Syndrome / Q000188:drug therapy / Q000276:immunology / Q000517:prevention & control; D014765:Viral Vaccines
chemical_list: D000998:Antiviral Agents; D014765:Viral Vaccines